Evidence map›Paper›PMID 41827678›Full record

ReviewCancers2026

Occurrence and Management of Acute, Subacute, and Delayed Toxicities in Patients with GEP-NETs Following Treatment with Radioligand Therapy.

Ghassan El-Haddad, Linda Gardner, Hyun Kim, Heloisa P Soares

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ghassan El-HaddadMoffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Linda GardnerNuclear Medicine and Theranostics, UCLA Health, Los Angeles, CA 90095, USA.ORCID 0000-0002-6338-3833
Hyun KimDepartment of Radiation Oncology, Washington University, St. Louis, MO 63110, USA.ORCID 0000-0003-4029-8764
Heloisa P SoaresHuntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0002-5185-2583

Funding

Novartis Pharmaceuticals Corporation N/A
6 · The paper itself

Abstract

Radioligand therapy (RLT) offers the ability to deliver radiation to specific cells based on the presence of certain targets. RLT with [

Indexed as

adverse eventgastroenteropancreatic neuroendocrine tumorsmanagementradiation safetyradioactive contaminationradioligand therapytoxicity

Identifiers

PMID41827678
PMCPMC12984351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.